References
1.
Rayner SG, Scholl Z, Mandrycky CJ, Chen J,
LaValley KN, Leary PJ, et al. Endothelial‐derived
von Willebrand factor accelerates fibrin clotting within engineered
microvessels. Journal of Thrombosis and Haemostasis
2022;20:1627–37. doi:10.1111/jth.15714.
2.
Smith NL, Rice KM, Bovill EG, Cushman M, Bis
JC, McKnight B, et al. Genetic variation associated
with plasma von Willebrand factor levels and the risk of incident venous
thrombosis. Blood 2011;117:6007–11.
doi:10.1182/blood-2010-10-315473.
3.
Goodeve A. Diagnosing von
Willebrand disease: genetic analysis. Hematology
2016;2016:678–82. doi:10.1182/asheducation-2016.1.678.
4.
Manderstedt E, Lind-Halldén C, Lethagen S,
Halldén C. Common and Rare Variants in Genes
Associated with von Willebrand Factor Level Variation: No Accumulation
of Rare Variants in Swedish von Willebrand Disease Patients.
TH Open 2020;04:e322–31. doi:10.1055/s-0040-1718885.
5.
Willebrand EA von. Hereditär pseudohemofili.
Finska Läkaresällskapets Handlingar 1926:87–112.
6.
Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ,
Hill FGH, Holmberg L, et al. Update on the
pathophysiology and classification of von Willebrand disease: a report
of the Subcommittee on von Willebrand Factor. Journal of
Thrombosis and Haemostasis 2006;4:2103–14. doi:10.1111/j.1538-7836.2006.02146.x.
7.
James PD, Connell NT, Ameer B, Di Paola J,
Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021
guidelines on the diagnosis of von Willebrand disease. Blood
Advances 2021;5:280–300. doi:10.1182/bloodadvances.2020003265.
8.
Batlle J, Pérez-Rodríguez A, Corrales I, Borràs
N, Costa Pinto J, López-Fernández MF, et al. Update
on Molecular Testing in von Willebrand Disease. Seminars in
Thrombosis and Hemostasis 2019;45:708–19. doi:10.1055/s-0039-1679922.
9.
Bodó
I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J.
Platelet‐dependent von Willebrand factor activity.
Nomenclature and methodology: communication from the SSC of the
ISTH. Journal of Thrombosis and Haemostasis
2015;13:1345–50. doi:10.1111/jth.12964.
10.
Abou-Ismail MY, James PD, Flood VH, Connell NT.
Beyond the guidelines: how we approach challenging
scenarios in the diagnosis and management of von Willebrand
disease. Journal of Thrombosis and Haemostasis
2023;21:204–14. doi:10.1016/j.jtha.2022.11.042.
11.
Salem RO, Van Cott EM. A
New Automated Screening Assay for the Diagnosis of von Willebrand
Disease. American Journal of Clinical Pathology
2007;127:730–5. doi:10.1309/cepnd3lfhq87xu4d.
12.
Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel
and chemiluminescent-based assay system for identification of, and
therapy monitoring in, von Willebrand disease. Thrombosis
Research 2016;141:202–11. doi:10.1016/j.thromres.2015.12.010.
13.
Schneppenheim R, Patzke J. Laboratory diagnosis of von Willebrand disease.
Hämostaseologie 2010;30:203–6. doi:10.1055/s-0037-1619057.
14.
Patzke J, Budde U, Huber A, Méndez A, Muth H,
Obser T, et al. Performance evaluation and
multicentre study of a von Willebrand factor activity assay based on
GPIb binding in the absence of ristocetin. Blood Coagulation
&Amp; Fibrinolysis 2014;25:860–70. doi:10.1097/mbc.0000000000000169.
15.
Othman M. Platelet-type
von Willebrand disease: a rare, often misdiagnosed and underdiagnosed
bleeding disorder. Seminars in Thrombosis and Hemostasis
2011;37:464–9. doi:10.1055/s-0031-1281030.
16.
Castaman G, Tosetto A, Cappelletti A, Goodeve
A, Federici AB, Batlle J, et al. Validation of a
rapid test (VWF-LIA) for the quantitative determination of von
Willebrand factor antigen in type 1 von Willebrand disease diagnosis
within the European multicenter study MCMDM-1VWD. Thrombosis
Research 2010;126:227–31. doi:10.1016/j.thromres.2010.06.013.
17.
Favaloro EJ, Mohammed S. Laboratory Testing for von Willebrand Factor Collagen
Binding (VWF:CB). Hemostasis and thrombosis, Springer New York;
2017, p. 417–33. doi:10.1007/978-1-4939-7196-1_31.
18.
Stufano F, Baronciani L, Mane‐Padros D, Cozzi
G, Faraudo S, Peyvandi F. A comparative evaluation
of a new fully automated assay for von Willebrand factor collagen
binding activity to an established method. Haemophilia
2017;24:156–61. doi:10.1111/hae.13371.
19.
Bowyer AE, Goodfellow KJ, Seidel H, Westhofen
P, Stufano F, Goodeve A, et al. Evaluation of a
semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von
Willebrand multimer, by two European Centers. Research and
Practice in Thrombosis and Haemostasis
2018;2:790–9. doi:10.1002/rth2.12141.
20.
Oliver S, Vanniasinkam T, Mohammed S, Vong R,
Favaloro EJ. Semi‐automated von Willebrand factor
multimer assay for von Willebrand disease: Further validation, benefits
and limitations. International Journal of Laboratory
Hematology 2019;41:762–71. doi:10.1111/ijlh.13107.
21.
Vangenechten I, Gadisseur A. Improving diagnosis of von Willebrand disease: Reference
ranges for von Willebrand factor multimer distribution.
Research and Practice in Thrombosis and Haemostasis
2020;4:1024–34. doi:10.1002/rth2.12408.
22.
Budde U, Pieconka A, Will K, Schneppenheim R.
Laboratory Testing for von Willebrand Disease:
Contribution of Multimer Analysis to Diagnosis and
Classification. Seminars in Thrombosis and Hemostasis
2006;32:514–21. doi:10.1055/s-2006-947866.
23.
Eikenboom J, Federici AB, Dirven RJ, Castaman
G, Rodeghiero F, Budde U, et al. VWF propeptide and
ratios between VWF, VWF propeptide, and FVIII in the characterization of
type 1 von Willebrand disease. Blood
2013;121:2336–9. doi:10.1182/blood-2012-09-455089.
24.
Sanders YV, Groeneveld D, Meijer K,
Fijnvandraat K, Cnossen MH, Bom JG van der, et al. von Willebrand factor propeptide and the phenotypic
classification of von Willebrand disease. Blood
2015;125:3006–13. doi:10.1182/blood-2014-09-603241.
25.
Stufano F, Boscarino M, Bucciarelli P,
Baronciani L, Maino A, Cozzi G, et al. Evaluation
of the Utility of von Willebrand Factor Propeptide in the Differential
Diagnosis of von Willebrand Disease and Acquired von Willebrand
Syndrome. Seminars in Thrombosis and Hemostasis
2018;45:036–42. doi:10.1055/s-0038-1660481.
26.
Pagliari MT, Budde U, Baronciani L, Eshghi P,
Ahmadinejad M, Badiee Z, et al. von Willebrand
factor neutralizing and non-neutralizing alloantibodies in 213 subjects
with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.
Journal of Thrombosis and Haemostasis
2023;21:787–99. doi:10.1016/j.jtha.2023.01.001.
27.
Mannucci P, Lombardi R, Bader R, Horellou M,
Finazzi G, Besana C, et al. Studies of the
pathophysiology of acquired von Willebrand’s disease in seven patients
with lymphoproliferative disorders or benign monoclonal
gammopathies. Blood 1984;64:614–21.
doi:10.1182/blood.v64.3.614.614.
28.
Haberichter SL, Castaman G, Budde U, Peake I,
Goodeve A, Rodeghiero F, et al. Identification of
type 1 von Willebrand disease patients with reduced von Willebrand
factor survival by assay of the VWF propeptide in the European study:
Molecular and Clinical Markers for the Diagnosis and Management of Type
1 VWD (MCMDM-1VWD). Blood
2008;111:4979–85. doi:10.1182/blood-2007-09-110940.
29.
Gudmundsdottir B, Arnfinnsdottir A, Kjeld M,
Ólafsson Ö, Önundarson P. Von Willebrand Factor
Does not Vary during Normal Menstrual Cycle. Thrombosis and
Haemostasis 2001;85:183–4. doi:10.1055/s-0037-1612925.
30.
Hillarp A, Ekholm C, Mattson E, Halldén C,
Friberg B, Lethagen S. Distribution of von
Willebrand factor levels in young women with and without bleeding
symptoms. Influence of ABO blood group and promoter haplotypes.
Thrombosis and Haemostasis 2008;99:1013–8.
doi:10.1160/th07-06-0419.
31.
Favaloro EJ, Lippi G. Preanalytical issues that may cause misdiagnosis in
haemophilia and von Willebrand disease. Haemophilia
2017;24:198–210. doi:10.1111/hae.13396.
32.
Favaloro EJ. Diagnosis and
classification of von Willebrand disease: a review of the differential
utility of various functional von Willebrand factor assays.
Blood Coagulation &Amp; Fibrinolysis
2011;22:553–64. doi:10.1097/mbc.0b013e32834a7e01.
33.
Favaloro EJ, Mohammed S, Vong R, Oliver S,
Brennan Y, Favaloro JW, et al. How we diagnose 2M
von Willebrand disease (VWD): Use of a strategic algorithmic approach to
distinguish 2M VWD from other VWD types. Haemophilia
2020;27:137–48. doi:10.1111/hae.14204.
34.
Goodeve A, Eikenboom J, Castaman G, Rodeghiero
F, Federici AB, Batlle J, et al. Phenotype and
genotype of a cohort of families historically diagnosed with type 1 von
Willebrand disease in the European study, Molecular and Clinical Markers
for the Diagnosis and Management of Type 1 von Willebrand Disease
(MCMDM-1VWD). Blood 2006;109:112–21.
doi:10.1182/blood-2006-05-020784.
35.
Flood VH, Christopherson PA, Gill JC, Friedman
KD, Haberichter SL, Bellissimo DB, et al. Clinical
and laboratory variability in a cohort of patients diagnosed with type 1
VWD in the United States. Blood
2016;127:2481–8. doi:10.1182/blood-2015-10-673681.
36.
Jong A de, Eikenboom J. Von Willebrand disease mutation spectrum and associated
mutation mechanisms. Thrombosis Research
2017;159:65–75. doi:10.1016/j.thromres.2017.09.025.
37.
Jokela V, Lassila R, Szanto T, Joutsi-Korhonen
L, Armstrong E, Oyen F, et al. Phenotypic and
genotypic characterization of 10 Finnish patients with von Willebrand
disease type 3: discovery of two main mutations.
Haemophilia 2013;19:e344–8. doi:10.1111/hae.12225.
38.
Tosetto A, Rodeghiero F, Castaman G, Goodeve A,
Federici AB, Batlle J, et al. A quantitative
analysis of bleeding symptoms in type 1 von Willebrand disease: results
from a multicenter European study (MCMDM‐1 VWD). Journal of
Thrombosis and Haemostasis 2006;4:766–73. doi:10.1111/j.1538-7836.2006.01847.x.
39.
Rodeghiero F, Tosetto A, Abshire T, Arnold DM,
Coller B, James P, et al. ISTH/SSC bleeding
assessment tool: a standardized questionnaire and a proposal for a new
bleeding score for inherited bleeding disorders. Journal of
Thrombosis and Haemostasis 2010;8:2063–5. doi:10.1111/j.1538-7836.2010.03975.x.
40.
Bowman M, Riddel J, Rand ML, Tosetto A, Silva
M, James PD. Evaluation of the diagnostic utility
for von Willebrand disease of a pediatric bleeding questionnaire.
Journal of Thrombosis and Haemostasis
2009;7:1418–21. doi:10.1111/j.1538-7836.2009.03499.x.
41.
Govorov I, Löfgren S, Chaireti R, Holmström M,
Bremme K, Mints M. Postpartum Hemorrhage in Women
with Von Willebrand Disease – A Retrospective Observational
Study. PLOS ONE 2016;11:e0164683.
doi:10.1371/journal.pone.0164683.
42.
Goodeve AC. The genetic
basis of von Willebrand disease. Blood Reviews
2010;24:123–34. doi:10.1016/j.blre.2010.03.003.
43.
Gudmundsdottir BR, Marder VJ, Onundarson PT.
Risk of excessive bleeding associated with
marginally low von Willebrand factor and mild platelet
dysfunction. Journal of Thrombosis and Haemostasis
2007;5:274–81. doi:10.1111/j.1538-7836.2007.02326.x.
44.
James PD, Lillicrap D. von
Willebrand disease: Clinical and laboratory lessons learned from the
large von Willebrand disease studies. American Journal of
Hematology 2012;87. doi:10.1002/ajh.23142.
45.
James PD, Notley C, Hegadorn C, Leggo J, Tuttle
A, Tinlin S, et al. The mutational spectrum of type
1 von Willebrand disease: results from a Canadian cohort study.
Blood 2006;109:145–54. doi:10.1182/blood-2006-05-021105.
46.
Asakura A, Harrison J, Gomperts E, Abildgaard
C. Type IIA von Willebrand disease with apparent
recessive inheritance. Blood
1987;69:1419–20. doi:10.1182/blood.v69.5.1419.1419.
47.
Meyer D, Fressinaud E, Gaucher C, Lavergne J-M,
Hilbert L, Ribba A-S, et al. Gene Defects in 150
Unrelated French Cases with Type 2 von Willebrand Disease: from the
Patient to the Gene. Thrombosis and Haemostasis
1997;78:451–6. doi:10.1055/s-0038-1657568.
48.
Enayat MS, Guilliatt AM, Surdhar GK, Jenkins
PV, Pasi KJ, Toh CH, et al. Aberrant dimerization
of von Willebrand factor as the result of mutations in the
carboxy-terminal region: identification of 3 mutations in members of 3
different families with type 2A (phenotype IID) von Willebrand
disease. Blood 2001;98:674–80. doi:10.1182/blood.v98.3.674.
49.
Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von
Willebrand disease. Best Practice &Amp; Research Clinical
Haematology 2001;14:281–98. doi:10.1053/beha.2001.0134.
50.
Federici A, Budde U, Castaman G, Drewke E, Krey
S, Mannucci P, et al. Von Willebrand Disease Type
2M “Vicenza” in Italian and German Patients: Identification
of the First Candidate Mutation (G3864A; R1205H) in 8 Families.
Thrombosis and Haemostasis 2000;83:136–40.
doi:10.1055/s-0037-1613769.
51.
Mazurier C, Goudemand J, Hilbert L, Caron C,
Fressinaud E, Meyer D. Type 2N von Willebrand
disease: clinical manifestations, pathophysiology, laboratory diagnosis
and molecular biology. Best Practice &Amp; Research
Clinical Haematology 2001;14:337–47. doi:10.1053/beha.2001.0138.
52.
Castaman G, Rodeghiero F, Tosetto A,
Cappelletti A, Baudo F, Eikenboom JCJ, et al. Hemorrhagic symptoms and bleeding risk in obligatory
carriers of type 3 von Willebrand disease: an international, multicenter
study. Journal of Thrombosis and Haemostasis
2006;4:2164–9. doi:10.1111/j.1538-7836.2006.02070.x.
53.
Schutgens REG, Jimenez-Yuste V, Escobar M,
Falanga A, Gigante B, Klamroth R, et al. Antithrombotic Treatment in Patients With Hemophilia: an
EHA-ISTH-EAHAD-ESO Clinical Practice Guidance.
HemaSphere 2023;7:e900. doi:10.1097/hs9.0000000000000900.
54.
Franchini M, Lippi G. Acquired von Willebrand syndrome: An update.
American Journal of Hematology 2006;82:368–75.
doi:10.1002/ajh.20830.
55.
Langer AL, Connell NT. Acquired von Willebrand Syndrome.
Hematology/Oncology Clinics of North America
2021;35:1103–16. doi:10.1016/j.hoc.2021.07.005.
56.
Lethagen S, Harris AS, Sjörin E, Nilsson IM.
Intranasal and Intravenous Administration of
Desmopressin: Effect on F VIII/vWF, Pharmacokinetics and
Reproducibility. Thrombosis and Haemostasis
1987;58:1033–6. doi:10.1055/s-0038-1646050.
57.
Lethagen S, Kyrle PA, Castaman G, Haertel S,
Mannucci PM. von Willebrand factor/factor VIII
concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective
multicenter trial in elective surgery. Journal of Thrombosis
and Haemostasis 2007;5:1420–30. doi:10.1111/j.1538-7836.2007.02588.x.
58.
Turitto VT, Weiss HJ. Red
Blood Cells: Their Dual Role in Thrombus Formation.
Science 1980;207:541–3. doi:10.1126/science.7352265.
59.
Lassila R, Weisel JW. Role of red blood cells
in clinically relevant bleeding tendencies and complications.
Journal of Thrombosis and Haemostasis
2023;21:3024–32. doi:10.1016/j.jtha.2023.05.009.
60.
Atiq F, Saes JL, Punt MC, Galen KPM van,
Schutgens REG, Meijer K, et al. Major differences in clinical
presentation, diagnosis and management of men and women with autosomal
inherited bleeding disorders. EClinicalMedicine
2021;32:100726. doi:10.1016/j.eclinm.2021.100726.
61.
Kirtava A, Drews C, Lally C, Dilley A, Evatt B.
Medical, reproductive and psychosocial experiences
of women diagnosed with von Willebrand’s disease receiving care in
haemophilia treatment centres: a case–control study.
Haemophilia 2003;9:292–7. doi:10.1046/j.1365-2516.2003.00756.x.
62.
Ragni MV, Machin N, Malec LM, James AH, Kessler
CM, Konkle BA, et al. Von Willebrand factor for
menorrhagia: a survey and literature review. Haemophilia
2016;22:397–402. doi:10.1111/hae.12898.
63.
Allen LH. Anemia and iron deficiency: Effects
on pregnancy outcome. The American Journal of Clinical
Nutrition 2000;71:1280S–1284S. doi:10.1093/ajcn/71.5.1280s.
64.
Skeith L, Rydz N, O’Beirne M, Goodyear D, Li H,
Poon M-C. Pregnancy loss in women with von
Willebrand disease: a single-center pilot study. Blood
Coagulation &Amp; Fibrinolysis 2017;28:393–7.
doi:10.1097/mbc.0000000000000620.
65.
Sekiya F, Yamashita T, Atoda H, Komiyama Y,
Morita T. Regulation of the Tertiary Structure and
Function of Coagulation Factor IX by Magnesium(II) Ions.
Journal of Biological Chemistry
1995;270:14325–31. doi:10.1074/jbc.270.24.14325.
66.
Siljander P, Lassila R. Studies of Adhesion-Dependent Platelet Activation:
Distinct Roles for Different Participating Receptors Can Be Dissociated
by Proteolysis of Collagen. Arteriosclerosis, Thrombosis, and
Vascular Biology 1999;19:3033–43. doi:10.1161/01.atv.19.12.3033.
67.
Peterson W, Tse B, Martin R, Fralick M,
Sholzberg M. Evaluating hemostatic thresholds for neuraxial anesthesia
in adults with hemorrhagic disorders and tendencies: A scoping review.
Research and Practice in Thrombosis and Haemostasis
2021;5:e12491. doi:10.1002/rth2.12491.
68.
Laffan MA, Lester W, O’Donnell JS, Will A, Tait
RC, Goodeve A, et al. The diagnosis and management
of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors
Organization guideline approved by the British Committee for Standards
in Haematology. British Journal of Haematology
2014;167:453–65. doi:10.1111/bjh.13064.
69.
Ahonen J, Stefanovic V, Lassila R. Management
of post‐partum haemorrhage. Acta Anaesthesiologica Scandinavica
2010;54:1164–78. doi:10.1111/j.1399-6576.2010.02309.x.
70.
UpToDate. Treatment
of iron deficiency anemia in adults 2023.
71.
Elbatarny M, Mollah S, Grabell J, Bae S,
Deforest M, Tuttle A, et al. Normal range of
bleeding scores for the ISTH‐BAT: adult and pediatric data from the
merging project. Haemophilia
2014;20:831–5. doi:10.1111/hae.12503.
72.
Sanders YV, Fijnvandraat K, Boender J,
Mauser‐Bunschoten EP, Bom JG van der, Meris J de, et al. Bleeding spectrum in children with moderate or severe von
Willebrand disease: Relevance of pediatric‐specific bleeding.
American Journal of Hematology 2015;90:1142–8.
doi:10.1002/ajh.24195.
73.
James AH, Jamison MG. Bleeding events and other complications during pregnancy
and childbirth in women with von Willebrand disease. Journal
of Thrombosis and Haemostasis 2007;5:1165–9.
doi:10.1111/j.1538-7836.2007.02563.x.
74.
Castaman G, James PD. Pregnancy and delivery in women with von Willebrand
disease. European Journal of Haematology
2019;103:73–9. doi:10.1111/ejh.13250.